IN THE NEWS

Merck doubles down on Skyhawk's tech to drug RNA, promising

$600M per autoimmune, metabolic target

​

When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after. Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.

The 20 under 40: Inside the next generation of biopharma leaders

​

U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both

the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy.

Celgene execs shell out $92M cash for a pair of R&D deals that

will fit perfectly in their new home at Bristol-Myers

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

​

Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also cover autoimmune and metabolic diseases.

IN THE NEWS

Merck doubles down on Skyhawk's tech to drug RNA, promising

$600M per autoimmune, metabolic target

​

When Merck signed on to discover candidates against neurodegeneration and cancer last July, Biogen was just expanding the list of neuro targets they want to go after. Now Merck is coming back for its own round two, adding autoimmune and metabolic diseases to the menu.

The 20 under 40: Inside the next generation of biopharma leaders

​

U-2 Dragon Lady, one of the conference rooms at Skyhawk Therapeutics’ office in Waltham, MA, is named after both

the American single-jet engine, high altitude reconnaissance aircraft and founder Kathleen McCarthy.

Celgene execs shell out $92M cash for a pair of R&D deals that

will fit perfectly in their new home at Bristol-Myers

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

WHAT WE DO

Our proprietary small molecule platform targets accelerates the discovery and development of drugs that correct RNA mis-splicing across a broad range of disease types:

ONCOLOGY

NEUROLOGY

INFLAMMATORY

INFECTIOUS

RARE

NEUROMUSCULAR

& METABOLIC